Nautilus Biotechnology Unveils Reproducible Single-Molecule Proteomics Data at Buck Institute
Nautilus Biotechnology Inc. has successfully installed its first external field evaluation unit at the Buck Institute for Research on Aging. Over six months, researchers generated reproducible data from neurodegenerative disease samples, revealing insights into tau proteoforms. These findings validate the platform's performance and its potential in understanding aging and neurodegeneration, including Alzheimer’s disease. Results will be presented at the 2025 HUPO World Congress seminar in Toronto.
Nautilus Biotechnology Inc. has announced the successful installation and testing of its first external field evaluation unit at the Buck Institute for Research on Aging. Over six months, researchers at the Buck Institute used Nautilus’ next-generation single-molecule proteomics platform to generate highly reproducible data from neurodegenerative disease samples, including novel insights into tau proteoforms. These results validate the platform’s robust performance and its potential to advance understanding of aging and neurodegeneration, such as Alzheimer’s disease. The scientific findings from this collaboration will be presented at the 2025 HUPO World Congress seminar, “Redefining Proteomics with Single-Molecule Iterative Mapping,” scheduled for November 10, 2025, in Toronto. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566730-en) on November 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
